Insider selling
Traded Dec 13, 2024 · filed 1 day laterNot reported under a pre-arranged trading plan
A Niagen Bioscience director sold $230K of Niagen Bioscience shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 7, 2025 · Filed Mar 10, 2025
Niagen Bioscience's SVP, General Counsel paid $2.1K out of pocket for Niagen Bioscience shares. Shares held went up 14% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$2,146
Shares × reported transaction price
<$25K
+13.8%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2024 ($409K)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-29. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
3 days after results of Mar 4, 2025, 61 days before results of May 7, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider selling
Traded Dec 13, 2024 · filed 1 day laterNot reported under a pre-arranged trading plan
A Niagen Bioscience director sold $230K of Niagen Bioscience shares. The filing does not indicate a pre-arranged trading plan.